D Li1, X Zhu2, H Wang3, N Li1. 1. Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. 2. Department of Radiation Oncology, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. Electronic address: zhuxx01@126.com. 3. Department of Cardiothoracic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
Abstract
PURPOSE: We explored the potential clinical association between programmed death-ligand 1 (PD-L1) expression and driven gene status in non-small cell lung cancer (NSCLC). METHODS: We systemically searched through October 2015. Odd ratios (ORs) with 95% CIs were calculated to examine the association of PD-L1 expression with driven gene status. A random- or fixed-effects model was used. RESULTS: Nine studies were identified. KRAS-mutant tumors were more likely to be PD-L1 positive than KRAS-wild type tumors (51% vs 36%; OR 1.69; 95% CI 1.01-2.84; p = 0.045). In contrast, PD-L1 expression did not differ by EGFR (OR 0.86; 95% CI 0.43-1.73; p = 0.675) or ALK (OR 1.02; 95% CI 0.44-2.37; p = 0.954) status. In subgroup analysis, there was also no significant association between PD-L1 expression and EGFR status in term of the cut-offs or ethnicity. CONCLUSION: In conclusion, NSCLC with KRAS mutations showed a trend for higher frequency of positive PD-L1 expression.
PURPOSE: We explored the potential clinical association between programmed death-ligand 1 (PD-L1) expression and driven gene status in non-small cell lung cancer (NSCLC). METHODS: We systemically searched through October 2015. Odd ratios (ORs) with 95% CIs were calculated to examine the association of PD-L1 expression with driven gene status. A random- or fixed-effects model was used. RESULTS: Nine studies were identified. KRAS-mutant tumors were more likely to be PD-L1 positive than KRAS-wild type tumors (51% vs 36%; OR 1.69; 95% CI 1.01-2.84; p = 0.045). In contrast, PD-L1 expression did not differ by EGFR (OR 0.86; 95% CI 0.43-1.73; p = 0.675) or ALK (OR 1.02; 95% CI 0.44-2.37; p = 0.954) status. In subgroup analysis, there was also no significant association between PD-L1 expression and EGFR status in term of the cut-offs or ethnicity. CONCLUSION: In conclusion, NSCLC with KRAS mutations showed a trend for higher frequency of positive PD-L1 expression.
Authors: Matthew Evans; Brendan O'Sullivan; Frances Hughes; Tina Mullis; Matthew Smith; Nicola Trim; Philippe Taniere Journal: Pathol Oncol Res Date: 2018-09-17 Impact factor: 3.201
Authors: Matthew A Coelho; Sophie de Carné Trécesson; Sareena Rana; Davide Zecchin; Christopher Moore; Miriam Molina-Arcas; Philip East; Bradley Spencer-Dene; Emma Nye; Karin Barnouin; Ambrosius P Snijders; Wi S Lai; Perry J Blackshear; Julian Downward Journal: Immunity Date: 2017-12-12 Impact factor: 31.745